IκB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges

Trends in Pharmacological Sciences

Volumn 28, Issue 3, 2007, Pages 142-148

  Strnad, Joann ^a   Burke, James R ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(AMINOCARBONYL)AMINO] 5 (4 FLUOROPHENYL) 3 THIOPHENECARBOXAMIDE; 2,2 DIFLUORO 1 (TRIFLUOROMETHYL)VINYL FLUOROMETHYL ETHER; 4 (2' AMINOETHYL)AMINO 1,8 DIMETHYLIMIDAZOL(1,2 A)QUINOXALINE; 5 BROMO 5 METHOXY BETA CARBOLINE; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; BMS 345541; CARBOLINE DERIVATIVE; CYCLOSPORIN A; GLUCOCORTICOID; I KAPPA B KINASE INHIBITOR; IMD 0354; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN KAPPA CHAIN; METHOTREXATE; ML 120B; N (6 CHLORO 7 METHOXY 9H BETA CARBOLIN 8 YL) 2 METHYLNICOTINAMIDE; N [3,5 BIS(TRIFLUOROMETHYL)PHENYL] 5 CHLORO 2 HYDROXYBENZAMIDE; NICOTINAMIDE DERIVATIVE; QUINOXALINE DERIVATIVE; THIOPHENE DERIVATIVE; TPCA 1; UNCLASSIFIED DRUG; ENZYME INHIBITOR; I KAPPA B KINASE;

AUTOIMMUNE DISEASE; DRUG EFFECT; EMBRYO DEVELOPMENT; HUMAN; INFECTION; INFECTION SENSITIVITY; INFLAMMATION; LIVER TOXICITY; LYMPHATIC SYSTEM DISEASE; LYMPHOPOIESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TERATOGENICITY; ANIMAL; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG THERAPY; IMMUNOLOGY; METHODOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; DRUG THERAPY; ENZYME INHIBITORS; HUMANS; I-KAPPA B KINASE; INFLAMMATION; MODELS, IMMUNOLOGICAL; MOLECULAR STRUCTURE;

EID: 33847168466     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.01.005     Document Type: Review

References (64)

1. Viemann D., et al. Transcriptional profiling of IKK2/NF-κB- and p38 MAP kinase-dependent gene expression in TNF-α-stimulated primary human endothelial cells. Blood 103 (2004) 3365-3373
2. Neurath M.F., et al. Role of NF-κB in immune and inflammatory responses in the gut. Gut 43 (1998) 856-860
3. Cho M.L., et al. STAT3 and NF-κB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J. Immunol. 176 (2006) 5652-5661
4. Zhang Z., et al. Interleukin-1β and tumor necrosis factor-α upregulate interleukin-23 subunit p19 gene expression in human colonic subepithelial myofibroblasts. Int. J. Mol. Med. 15 (2005) 79-83
5. He K.L., and Ting A.T. Essential role for IKKγ/NEMO in TCR-induced IL-2 expression in Jurkat T cells. Eur. J. Immunol. 33 (2003) 1917-1924
6. Snapper C.M., et al. B cells from p50/NF-κB knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching. J. Immunol. 156 (1996) 183-191
7. Ruocco M.G., et al. IκB kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 201 (2005) 1677-1687
8. Pattoli M.A., et al. Collagen and aggrecan degradation is blocked in interleukin-1-treated cartilage explants by an inhibitor of IκB kinase through suppression of metalloproteinase expression. J. Pharmacol. Exp. Ther. 315 (2005) 382-388
9. Saklatvala J. Glucocorticoids: do we know how they work?. Arthritis Res. 4 (2002) 146-150
10. Whiteside S.T., and Israel A. IκB proteins: structure, function and regulation. Sem. Cancer Biol. 8 (1997) 75-82
11. Ghosh S., and Karin M. Missing pieces in the NF-κB puzzle. Cell 109 (2002) S81-S96
12. Schomer-Miller B., et al. Regulation of IκB kinase (IKK) complex by IKKγ-dependent phosphorylation of the T-loop and C terminus of IKKβ. J. Biol. Chem. 281 (2006) 15268-15276
13. Senftleben U., et al. Activation by IKKα of a second, evolutionary conserved. NF-κB signaling pathway. Science 293 (2001) 1495-1499
14. Anest V., et al. A nucleosomal function for IκB kinase-α in NF-κB-dependent gene expression. Nature 423 (2003) 659-663
15. Dejardin E. The alternative NF-κB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem. Pharmacol. 72 (2006) 1161-1179
16. Lawrence T., et al. IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation. Nature 434 (2005) 1138-1143
17. Podolin P.L., et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J. Pharmacol. Exp. Ther. 312 (2005) 373-381
18. Burke J.R., et al. BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice. J. Biol. Chem. 278 (2003) 1450-1456
19. Ziegelbauer K., et al. A selective novel low-molecular-weight inhibitor of IκB kinase-β (IKK-β) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br. J. Pharmacol. 145 (2005) 178-192
20. Wen D., et al. A selective small molecule IκB kinase β inhibitor blocks nuclear factor κB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. J. Pharmacol. Exp. Ther. 317 (2006) 989-1001
21. Birrell M.A., et al. Iκ-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. Am. J. Respir. Crit. Care Med. 172 (2005) 962-971
22. MacMaster J.F., et al. An inhibitor of IκB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice. Inflamm. Res. 52 (2003) 508-511
23. McIntyre K.W., et al. A highly selective inhibitor of IκB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum. 48 (2003) 2652-2659
24. Seetharaman R., et al. Essential role of T cell NF-κB activation in collagen-induced arthritis. J. Immunol. 163 (1999) 1577-1583
25. Schopf L., et al. IKKβ inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. Arthritis Rheum. 54 (2006) 3163-3173
26. Dai S., et al. The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J. Biol. Chem. 279 (2004) 37219-37222
27. Cottone M., et al. Infliximab and ulcerative colitis. Expert Opin. Biol. Ther. 6 (2006) 401-408
28. van Assche G., and Rutgeerts P. Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm. Bowel Dis. 8 (2002) 291-300
29. Yang L., et al. Essential role of nuclear factor κB in the induction of eosinophilia in allergic airway inflammation. J. Exp. Med. 188 (1998) 1739-1750
30. Townsend R.M., et al. A highly selective inhibitor of IκB kinase, BMS-345541, augments graft survival mediated by suboptimal immunosuppression in a murine model of cardiac graft rejection. Transplantation 77 (2004) 1090-1094
31. Herrmann O., et al. IKK mediates ischemia-induced neuronal death. Nat. Med. 11 (2005) 1322-1329
32. Luo J.L., et al. IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy. J. Clin. Invest. 115 (2005) 2625-2632
33. Karin M., and Greten F.R. NF-κB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5 (2005) 749-759
34. Davis R.E., et al. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194 (2001) 1861-1874
35. Lam L.T., et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin. Cancer Res. 11 (2005) 28-40
36. Yang J., et al. BMS-345541 targets inhibitor of κB kinase and induces apoptosis in melanoma: involvement of nuclear factor κB and mitochondria pathways. Clin. Cancer Res. 12 (2006) 950-960
37. Nakanishi C., and Toi C. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 5 (2005) 297-309
38. Gao Z., et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor κB kinase complex. J. Biol. Chem. 277 (2002) 48115-48121
39. Cai D., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat. Med. 11 (2005) 183-190
40. Arkan M.C., et al. IKK-β links inflammation to obesity-induced insulin resistance. Nat. Med. 11 (2005) 191-198
41. Kamon J., et al. A novel IKKβ inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance. Biochem. Biophys. Res. Commun. 323 (2004) 242-248
42. Li Q., et al. Severe liver degeneration in mice lacking the IκB kinase 2 gene. Science 284 (1999) 321-325
43. Beg A.A., et al. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 376 (1995) 167-170
44. Li Z.W., et al. The IKKβ subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis. J. Exp. Med. 189 (1999) 1839-1845
45. Hu Y., et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKα subunit of IκB kinase. Science 284 (1999) 316-320
46. Li Q., et al. IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev. 13 (1999) 1322-1328
47. Hu Y., et al. IKKα controls formation of the epidermis independently of NF-κB. Nature 410 (2001) 710-714
48. Lavon I., et al. High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-κB activation. Nat. Med. 6 (2000) 573-577
49. Maeda S., et al. IKKβ is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFα. Immunity 19 (2003) 725-737
50. Maeda S., et al. IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005) 977-990
51. Uesugi T., et al. Delivery of IκB superrepressor gene with adenovirus reduces early alcohol-induced liver injury in rats. Hepatology 34 (2001) 1149-1157
52. Luedde T., et al. Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J. Clin. Invest. 115 (2005) 849-859
53. Nagashima K., et al. Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKβ. Blood 107 (2006) 4266-4273
54. Senftleben U., et al. IKKβ is essential for protecting T cells from TNFα-induced apoptosis. Immunity 14 (2001) 217-230
55. Nakagawa M., et al. The effect of glucocorticoids on the expression of L-selectin on polymorphonuclear leukocyte. Blood 93 (1999) 2730-2737
56. Li Z.W., et al. IKK β is required for peripheral B cell survival and proliferation. J. Immunol. 170 (2003) 4630-4637
57. Pasparakis M., et al. IκB kinase signaling is essential for maintenance of mature B cells. J. Exp. Med. 196 (2002) 743-752
58. Sasaki Y., et al. Canonical NF-κB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity 24 (2006) 729-739
59. Ren H., et al. I-κB kinases α and β have distinct roles in regulating murine T cell function. J. Immunol. 168 (2002) 3721-3731
60. Schmidt-Supprian M., et al. Mature T cells depend on signaling through the IKK complex. Immunity 19 (2003) 377-389
61. Kaisho T., et al. IκB kinase α is essential for mature B cell development and function. J. Exp. Med. 193 (2001) 417-426
62. Schiemann B., et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293 (2001) 2111-2114
63. Puel A., et al. Inherited disorders of NF-κB-mediated immunity in man. Curr. Opin. Immunol. 16 (2004) 34-41
64. Orange J.S., et al. Human disease resulting from gene mutations that interfere with appropriate nuclear factor-κB activation. Imm. Rev 203 (2005) 21-37